Why the study?
GDMT prescription and adherence in India are low, with MRAs being the least prescribed, leaving an unmet need to identify gaps and formulate mitigation strategies.
Answers are grounded in this paper and cite their sources.
Highlights the underutilization of MRAs in heart failure patients in India and the need for strategies to improve GDMT adoption.
Early initiation of guideline-directed medical therapies (GDMTs) in heart failure (HF) and their uptitration to the target dose confer mortality benefits and reduce the risk of readmission. GDMT nonuse is a significant predictor of mortality in HF patients. However, GDMT prescription and adherence in India are low. Of the GDMTs, mineralocorticoid receptor antagonists (MRAs) are the least prescribed. There are multilevel gaps [healthcare professional (HCP)-related, patient-related] in the adoption and use of MRAs in HF. There is an unmet need to identify these gaps and formulate mitigation strategies to close them. This can improve or enhance GDMT adoption in the HF treatment paradigm.
No takes yet. Share an insight, caveat, or question.
Gautam et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: